Key result
Nootkatone reduced doxorubicin-induced myocardial damage, decreasing plasma troponin I levels from 5.958 ug/L to 2.334 ug/L.
Why the study?
Doxorubicin clinical use is limited by serious cardiotoxicity leading to heart failure, while nootkatone possesses antioxidant and anti-inflammatory properties that may offer protection.
Does Nootkatone prevent doxorubicin-induced myocardial injury in a mouse model?
Does Nootkatone prevent doxorubicin-induced myocardial injury in a mouse model?
Nootkatone demonstrates cardioprotective effects against doxorubicin-induced myocardial injury in mice by reducing oxidative stress and inflammation.
Answers are grounded in this paper and cite their sources.
May attenuate doxorubicin cardiotoxicity in rodents; leaves open translation to human cardioprotection.
BACKGROUND/AIMS: Doxorubicin (DOXO) is a potent chemotherapeutic drug that is used in the treatment of a large number of cancers. Despite its important chemotherapeutic characteristics, its usage is limited because of the serious side effects; the most noticeable is cardiotoxicity which can manifest acutely or years after completion of treatment leading to left ventricular dysfunction, dilated cardiomyopathy and heart failure. Nootkatone (NK) is a recognized bioactive compound isolated from the heartwood of Cupressus nootkatensis and has been reported to have antiseptic, antioxidant, and anti-allergic activities. METHODS: Male C57B6/J mice were used for mice model of DOXO-cardiac toxicity. Mice were given either DOXO or NK or DOXO+NK or vehicle (normal saline) after which the mice again had free access to food and water. Heart and plasma samples were collected 5 days after DOXO administration and were used for immunohistochemistry, electron microscopy and enzyme linked immunosorbent assay (ELISA). RESULTS: There were significant reduction in inflammatory markers in hearts of DOXO-NK- treated mice when compared with DOXO-treated mice. Moreover, there were significant increase in antioxidant proteins and reduction of oxidative stress in hearts of DOXO-NK-treated mice when compared with DOXO-treated mice. There was a significant reduction in myocardial damage as shown by significant reduction of troponin I in DOXO-NK- treated mice when compared with DOXO-treated mice. CONCLUSION: Nootkatone improves DOXO-induced myocardial injury through modulation of NF-κB signals and reduction of oxidative stress.
No takes yet. Share an insight, caveat, or question.
Al‐Salam et al. (2022) studied Doxorubicin-induced myocardial injury (n=40). Nootkatone vs. Doxorubicin alone was evaluated on Plasma Troponin I concentration (ug/L) (p=<0.001). Nootkatone reduced doxorubicin-induced myocardial damage, decreasing plasma troponin I levels from 5.958 ug/L to 2.334 ug/L.
Synapse has enriched 10 related papers. Consider them for comparative context: